



Doc

3653
Iaw

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

10/522,324

Filing Date

01/25/2005

First Named Inventor

Michael Birsha DAVIES

Art Unit

3653

Examiner Name

To be assigned

Attorney Docket Number

PG4886A USW

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		
Applicants believe that no fee is required for this submission. However, the Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	GlaxoSmithKline		
Signature			
Printed name	J. Michael Strickland		
Date	February 22, 2006	Reg. No.	47,115

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the

Signature			
Typed or printed name	Johnnie Jones	Date	February 22, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Michael Birsha DAVIES

Serial No.: 10/522,324

Art Unit: 3653

Filing Date: January 25, 2005

Examiner: To be assigned

For: *Medicament Dispenser*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- [X] Copies of the following references are enclosed. References # 28-56
[] Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))
[] A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

[] The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. [] The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

[] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

[] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).


C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- [] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

J. Michael Strickland, Attorney of Record
Registration No. 47,115

Date: February 22, 2006
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-9024
Facsimile: (919) 483-5730

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: February 22, 2006


Johnie Jones


**FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT**

ATTORNEY DOCKET NO. PG4886-A USW	SERIAL NO. 10/522,324
APPLICANT Michael Birsha DAVIES	
FILING DATE 01/25/2005	GROUP 3653

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1. 3,269,389	08/30/1966	Meurer et al.			
	2. 4,330,835	05/18/1982	Gehm			
	3. 4,627,432	12/09/1986	Newell et al.			
	4. 4,778,054	10/18/1988	Newell et al.			
	5. 4,811,731	03/14/1989	Newell et al.			
	6. 4,940,966	07/10/1990	Pettigrew et al.			
	7. 5,007,419	04/16/1991	Weinstein et al.			
	8. 5,437,267	08/01/1995	Weinstein et al.			
	9. 5,437,270	08/01/1995	Braithwaite			
	10. 5,462,205	10/31/1995	Keller			
	11. 5,497,765	03/12/1996	Praud et al.			
	12. 5,505,704	04/09/1996	Pawelka et al.			
	13. 5,552,438	09/03/1996	Christensen IV			
	14. 5,590,645	01/07/1997	Davies et al.			

Continue on page 2
FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
28.	1461280	02/27/1969	DE			X
29.	1387954	03/19/1975	GB			
30.	0009291	04/02/1980	EP			
31.	0009293	04/02/1980	EP			
32.	0372777	06/13/1990	EP			
33.	2242134	09/25/1991	GB			
34.	0469814	02/05/1992	EP			
35.	92/12402	07/23/1992	PCT			
36.	0521434	01/07/1993	EP			
37.	4305277	08/25/1994	DE			X
38.	96/31790	10/10/1996	PCT			
39.	98/30332	07/16/1998	PCT			
40.	98/34664	08/13/1998	PCT			
41.	98/51257	11/19/1998	PCT			
42.	2327408	01/27/1999	GB			
43.	99/39991	08/12/1999	PCT			
44.	99/47505	09/23/1999	PCT			
45.	00/00411	01/06/2000	PCT			

Continue on page 2
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

EXAMINER	DATE CONSIDERED

Continue on page 2

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PG4886-A USW	SERIAL NO. 10/522,324
				APPLICANT Michael Birsha DAVIES	
				FILING DATE 01/25/2005	GROUP 3653

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	15.	5,664,557	09/09/1997	Makiej, Jr.			
	16.	5,772,085	06/30/1998	Bryant et al.			
	17.	5,778,873	07/14/1998	Braithwaite			
	18.	5,830,490	11/03/1998	Weinstein et al.			
	19.	5,860,419	01/19/1999	Davies et al.			
	20.	5,873,360	02/23/1999	Davies et al.			
	21.	5,901,883	05/11/1999	Ritsche			
	22.	5,941,241	08/24/1999	Weinstein et al.			
	23.	6,029,663	02/29/2000	Eisele et al.			
	24.	6,116,237	09/21/2000	Schultz et al.			
	25.	2001/027789	10/11/2001	Goede et al.			
	26.	6,234,167	05/22/2002	Cox et al.			
	27.	2004/0050864	03/18/2004	Stradella			

Continue on page _____

FOREIGN PATENT DOCUMENTS (Cont'd)

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	46.	00/45879	08/10/2000	PCT			
	47.	00/64520	11/02/2000	PCT			
	48.	01/17595	03/15/2001	PCT			
	49.	01/24690	04/12/2001	PCT			
	50.	01/26020	04/12/2001	PCT			
	51.	01/26021	04/12/2001	PCT			
	52.	01/41849	06/14/2001	PCT			
	53.	01/68169	09/20/2001	PCT			
	54.	01/98176	12/27/2001	PCT			
	55.	1300171	04/09/2003	EP			
	56.	03/061744	07/31/2003	PCT			

Continue on page _____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

Continue on page _____

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.